Meiji Yasuda Asset Management Co Ltd. Sells 457 Shares of Humana Inc. (NYSE:HUM)

Meiji Yasuda Asset Management Co Ltd. reduced its holdings in shares of Humana Inc. (NYSE:HUM – Get Rating) by 13.8% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 2,847 shares of the insurance provider’s stock after selling 457 shares during the quarter. Meiji Yasuda Asset Management Co Ltd.’s holdings in Humana were worth $1,381,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of HUM. Cibc World Market Inc. lifted its stake in shares of Humana by 4.0% during the 1st quarter. Cibc World Market Inc. now owns 5,709 shares of the insurance provider’s stock valued at $2,484,000 after buying an additional 217 shares in the last quarter. Blair William & Co. IL increased its holdings in shares of Humana by 0.6% in the 1st quarter. Blair William & Co. IL now owns 5,660 shares of the insurance provider’s stock worth $2,463,000 after buying an additional 32 shares during the last quarter. Cetera Investment Advisers increased its holdings in shares of Humana by 0.5% in the 1st quarter. Cetera Investment Advisers now owns 4,906 shares of the insurance provider’s stock worth $2,135,000 after buying an additional 26 shares during the last quarter. Sequoia Financial Advisors LLC increased its holdings in shares of Humana by 19.0% in the 1st quarter. Sequoia Financial Advisors LLC now owns 615 shares of the insurance provider’s stock worth $268,000 after buying an additional 98 shares during the last quarter. Finally, Candriam Luxembourg S.C.A. increased its holdings in shares of Humana by 25.0% in the 1st quarter. Candriam Luxembourg S.C.A. now owns 29,809 shares of the insurance provider’s stock worth $12,971,000 after buying an additional 5,964 shares during the last quarter. 93.38% of the stock is currently owned by hedge funds and other institutional investors.

Humana Stock Performance

Shares of HUM stock opened at $481.97 on Wednesday. The company has a 50 day moving average price of $494.76 and a 200-day moving average price of $507.59. Humana Inc. has a 52 week low of $410.87 and a 52 week high of $571.30. The firm has a market capitalization of $60.23 billion, a PE ratio of 21.87, a P/E/G ratio of 1.20 and a beta of 0.72. The company has a quick ratio of 1.52, a current ratio of 1.52 and a debt-to-equity ratio of 0.59.

Humana (NYSE:HUM – Get Rating) last announced its quarterly earnings results on Wednesday, February 1st. The insurance provider reported $1.62 EPS for the quarter, topping analysts’ consensus estimates of $1.46 by $0.16. Humana had a net margin of 3.02% and a return on equity of 20.50%. The firm had revenue of $22.44 billion during the quarter, compared to analyst estimates of $22.45 billion. During the same period in the previous year, the business posted $1.24 earnings per share. The business’s revenue for the quarter was up 6.6% on a year-over-year basis. As a group, equities research analysts expect that Humana Inc. will post 28.04 earnings per share for the current year.

Humana Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, April 28th. Investors of record on Friday, March 31st will be given a dividend of $0.885 per share. This represents a $3.54 annualized dividend and a yield of 0.73%. This is a positive change from Humana’s previous quarterly dividend of $0.79. The ex-dividend date of this dividend is Thursday, March 30th. Humana’s payout ratio is 14.29%.

Insider Activity at Humana

In related news, insider Timothy S. Huval sold 635 shares of the business’s stock in a transaction that occurred on Friday, December 16th. The shares were sold at an average price of $497.71, for a total transaction of $316,045.85. Following the completion of the sale, the insider now directly owns 4,968 shares in the company, valued at $2,472,623.28. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, insider Timothy S. Huval sold 635 shares of the business’s stock in a transaction that occurred on Friday, December 16th. The shares were sold at an average price of $497.71, for a total transaction of $316,045.85. Following the completion of the sale, the insider now directly owns 4,968 shares in the company, valued at $2,472,623.28. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director David A. Jr/Ky Jones sold 15,000 shares of the business’s stock in a transaction that occurred on Wednesday, December 21st. The shares were sold at an average price of $501.72, for a total transaction of $7,525,800.00. Following the sale, the director now owns 42,028 shares of the company’s stock, valued at $21,086,288.16. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 35,258 shares of company stock worth $17,772,482. 0.39% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of equities analysts have recently commented on HUM shares. StockNews.com raised shares of Humana from a “buy” rating to a “strong-buy” rating in a report on Wednesday. TheStreet lowered shares of Humana from a “b” rating to a “c+” rating in a report on Wednesday, February 1st. Truist Financial reduced their target price on shares of Humana from $580.00 to $560.00 and set a “hold” rating on the stock in a report on Tuesday, February 7th. The Goldman Sachs Group raised shares of Humana from a “neutral” rating to a “buy” rating and increased their target price for the company from $575.00 to $652.00 in a report on Tuesday, December 13th. Finally, JPMorgan Chase & Co. reduced their target price on shares of Humana from $630.00 to $625.00 and set an “overweight” rating on the stock in a report on Friday, January 6th. Two analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $594.12.

Humana Profile

(Get Rating)

Humana Inc engages in the provision of health insurance services. The firm operates through the following segments: Retail, Group and Specialty and Healthcare Services. The Retail segment consists of products sold on a retail basis to individuals including medical and supplemental plans such as Medicare, and State-based contracts.